LCTX
Lineage Cell Therapeutics, Inc.
There isn't enough reported data to score LCTX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
LCTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
LCTX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
LCTX PE Valuation
LCTX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
LCTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCTX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LCTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$0.12 | +$0.01 |
| Q2 2024 | -$0.14 | -$0.01 |
| Q1 2024 | -$0.14 | $0.00 |
| Q4 2023 | -$0.13 | +$0.02 |
| Q3 2023 | -$0.13 | +$0.16 |
| Q2 2023 | -$0.13 | +$0.17 |
| Q1 2023 | -$0.14 | +$0.15 |
| Q4 2022 | -$0.15 | +$0.11 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 175% for LCTX versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
LCTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4M | -61% |
| Q2 2026 | $1.1M | -61% |
| Q1 2026 | $1.7M | +15% |
| Q4 2025 | $6.6M | +130% |
| Q3 2025 | $3.7M | -2.6% |
| Q2 2025 | $2.8M | +96% |
| Q1 2025 | $1.5M | +4% |
| Q4 2024 | $2.9M | +37% |
LCTX's revenue has held roughly level: $1M last quarter, down 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -510% | -407 points |
| Q2 2026 | -835% | -119 points |
| Q1 2026 | -440% | -7.1 points |
| Q4 2025 | -99% | +79 points |
| Q3 2025 | -103% | -1.2 points |
| Q2 2025 | -715% | -299 points |
| Q1 2025 | -433% | +28 points |
| Q4 2024 | -178% | +127 points |
LCTX's operating margin was −510% last quarter, down 407 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over LCTX on profitability, with a higher operating margin.
LCTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.7M | -$2.1M |
| Q2 2026 | -$7.4M | -$1.8M |
| Q1 2026 | -$8.1M | -$3.2M |
| Q4 2025 | -$5.3M | +$1.4M |
| Q3 2025 | -$3.6M | +$2.3M |
| Q2 2025 | -$5.6M | -$327K |
| Q1 2025 | -$5M | +$838K |
| Q4 2024 | -$6.7M | -$601K |
LCTX has burned cash in almost every quarter: −$26M over the past year, against −$21M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over LCTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -2.4M shares |
| 1 year | +13% | +30.2M shares |
| 3 years | +52% | +88.5M shares |
| 5 years | +73% | +109M shares |
LCTX has 259M diluted shares, up 13% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over LCTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
LCTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.1x | Net Cash |
| Q2 2023 | -0.3x | Net Cash |
LCTX has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
LCTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 39.4 | Neutral |
LCTX's weekly RSI is 40 (neutral) and its Stochastic is 39 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
LCTX PE vs Healthcare Sector
LCTX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
LCTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 0% above |
| 20 week MA | $1.07 | 7.5% below |
| 50 week MA | $1.35 | 27% below |
| 100 week MA | $1.16 | 15% below |
| 200 week MA | $1.15 | 14% below |
LCTX is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over LCTX on trend strength, trading above more of its moving averages.
LCTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.77 | $1.76 | +129% |
| 2021 | $1.76 | $2.68 | +52% |
| 2022 | $2.68 | $1.09 | -59% |
| 2023 | $1.09 | $1.09 | 0% |
| 2024 | $1.09 | $0.50 | -54% |
| 2025 | $0.50 | $1.65 | +230% |
| 2026 YTD | $1.65 | $0.99 | -40% |
LCTX's yearly returns have swung widely, from +230% in 2025 to −59% in 2022. It's down 40% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over LCTX on returns for 2026, with the stronger performance.